Cannabidiol (CBD), a non-psychoactive compound from Cannabis Sativa, has gained attention for its diverse therapeutic potential. This review explores CBD's pharmacokinetics, including bioavailability, distribution, safety, and dosage, as well as its pharmacological effects on the endocannabinoid system and ion channels. CBD exhibits anti-inflammatory and antioxidant properties, influencing pathways like Interferon-beta and NF-κB, making it a versatile candidate for immune regulation and inflammatory diseases. Historically, Cannabis has been used for medicinal purposes, and CBD's role as a phytocannabinoid is increasingly recognized. Research highlights CBD's potential in clinical applications, including epilepsy, Alzheimer's, Parkinson's, and multiple sclerosis, with promising results in preclinical and clinical studies. CBD's pharmacokinetics vary by administration route, with oral bioavailability limited to 6%, while inhalation and transdermal routes offer higher bioavailability. CBD is metabolized primarily by CYP2C19 and CYP3A4, with potential drug interactions affecting other medications. Safety profiles show CBD to be well-tolerated, with mild side effects, though liver enzyme elevations may occur. CBD's anti-inflammatory effects are mediated through inhibition of endocannabinoid signaling, modulation of ion channels, and interaction with adenosine and GABA receptors. It shows promise in treating pain, autoimmune diseases, heart conditions, and diabetes, with ongoing clinical trials exploring its efficacy. CBD also exhibits antiviral properties against SARS-CoV-2, though clinical trials have not shown significant therapeutic benefits. Overall, CBD's multifaceted pharmacological profile suggests its potential in various therapeutic applications, warranting further research and clinical validation.Cannabidiol (CBD), a non-psychoactive compound from Cannabis Sativa, has gained attention for its diverse therapeutic potential. This review explores CBD's pharmacokinetics, including bioavailability, distribution, safety, and dosage, as well as its pharmacological effects on the endocannabinoid system and ion channels. CBD exhibits anti-inflammatory and antioxidant properties, influencing pathways like Interferon-beta and NF-κB, making it a versatile candidate for immune regulation and inflammatory diseases. Historically, Cannabis has been used for medicinal purposes, and CBD's role as a phytocannabinoid is increasingly recognized. Research highlights CBD's potential in clinical applications, including epilepsy, Alzheimer's, Parkinson's, and multiple sclerosis, with promising results in preclinical and clinical studies. CBD's pharmacokinetics vary by administration route, with oral bioavailability limited to 6%, while inhalation and transdermal routes offer higher bioavailability. CBD is metabolized primarily by CYP2C19 and CYP3A4, with potential drug interactions affecting other medications. Safety profiles show CBD to be well-tolerated, with mild side effects, though liver enzyme elevations may occur. CBD's anti-inflammatory effects are mediated through inhibition of endocannabinoid signaling, modulation of ion channels, and interaction with adenosine and GABA receptors. It shows promise in treating pain, autoimmune diseases, heart conditions, and diabetes, with ongoing clinical trials exploring its efficacy. CBD also exhibits antiviral properties against SARS-CoV-2, though clinical trials have not shown significant therapeutic benefits. Overall, CBD's multifaceted pharmacological profile suggests its potential in various therapeutic applications, warranting further research and clinical validation.